Chimerix’s (CMRX) Neutral Rating Reaffirmed at HC Wainwright

Chimerix (NASDAQ:CMRX)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $8.55 target price on the biopharmaceutical company’s stock, down from their prior target price of $11.00. HC Wainwright’s price objective would suggest a potential upside of 1.48% from the stock’s current price.

Separately, Wedbush reaffirmed an “outperform” rating and set a $7.00 target price (up from $6.00) on shares of Chimerix in a research report on Tuesday, February 18th.

Chimerix Price Performance

CMRX stock traded up $3.47 during mid-day trading on Wednesday, reaching $8.43. The company had a trading volume of 103,968,344 shares, compared to its average volume of 1,904,366. The firm has a 50 day moving average of $4.04 and a 200 day moving average of $2.17. Chimerix has a 12 month low of $0.75 and a 12 month high of $8.44. The company has a market capitalization of $757.71 million, a PE ratio of -8.96 and a beta of 0.32.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 20,760 shares of company stock valued at $91,175. Company insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bender Robert & Associates bought a new stake in shares of Chimerix in the 4th quarter valued at about $37,000. Susquehanna Fundamental Investments LLC acquired a new stake in Chimerix in the fourth quarter valued at approximately $59,000. Jane Street Group LLC purchased a new position in Chimerix in the fourth quarter worth $62,000. Diadema Partners LP acquired a new position in shares of Chimerix during the fourth quarter worth $101,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Chimerix during the 4th quarter valued at $130,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.